BBZA — BB Biotech AG Cashflow Statement
0.000.00%
- €1.64bn
- -€45.51m
- CH₣112.24m
- 91
- 75
- 17
- 68
Annual cashflow statement for BB Biotech AG, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Changes in Working Capital | -46.7 | -59.5 | -44.3 | -35.3 | -31.1 |
Other Operating Cash Flow | |||||
Cash from Operating Activities | 262 | -94.8 | 231 | 218 | 305 |
Financing Cash Flow Items | -0.883 | -0.986 | -1.73 | -5.8 | -4.98 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -284 | 91.8 | -233 | -220 | -305 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -23.9 | -3.98 | -0.887 | -1.45 | -0.043 |